Myostatin (also known as growth and differentiation factor 8) is a secreted member of the transforming growth factor-β (TGF-β) family that is mainly expressed in skeletal muscle, which is also its primary target tissue. Deletion of the myostatin gene (Mstn) in mice leads to muscle hypertrophy, and animal studies support the concept that myostatin is a negative regulator of muscle growth and regeneration1,2,3,4,5. However, myostatin deficiency also increases bone formation, mainly through loading-associated effects on bone6,7,8,9,10,11. Here we report a previously unknown direct role for myostatin in osteoclastogenesis and in the progressive loss of articular bone in rheumatoid arthritis (RA). We demonstrate that myostatin is highly expressed in the synovial tissues of RA subjects and of human tumor necrosis factor (TNF)-α transgenic (hTNFtg) mice, a model for human RA12. Myostatin strongly accelerates receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast formation in vitro through transcription factor SMAD2-dependent regulation of nuclear factor of activated T-cells (NFATC1). Myostatin deficiency or antibody-mediated inhibition leads to an amelioration of arthritis severity in hTNFtg mice, chiefly reflected by less bone destruction. Consistent with these effects in hTNFtg mice, the lack of myostatin leads to increased grip strength and less bone erosion in the K/BxN serum-induced arthritis model in mice. The results strongly suggest that myostatin is a potent therapeutic target for interfering with osteoclast formation and joint destruction in RA.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
McPherron, A.C., Lawler, A.M. & Lee, S.J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387, 83–90 (1997).
Huang, Z., Chen, X. & Chen, D. Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. Cell. Signal. 23, 1441–1446 (2011).
Lin, J. et al. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem. Biophys. Res. Commun. 291, 701–706 (2002).
Wagner, K.R., Liu, X., Chang, X. & Allen, R.E. Muscle regeneration in the prolonged absence of myostatin. Proc. Natl. Acad. Sci. USA 102, 2519–2524 (2005).
McCroskery, S. et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J. Cell Sci. 118, 3531–3541 (2005).
Kellum, E. et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 44, 17–23 (2009).
Hamrick, M.W. et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 40, 1544–1553 (2007).
Hamrick, M.W. Increased bone mineral density in the femora of GDF8 knockout mice. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 272, 388–391 (2003).
Hamrick, M.W., Pennington, C. & Byron, C.D. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J. Orthop. Res. 21, 1025–1032 (2003).
Nicholson, E.K., Stock, S.R., Hamrick, M.W. & Ravosa, M.J. Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice. Arch. Oral Biol. 51, 37–49 (2006).
Bialek, P. et al. A myostatin and activin decoy receptor enhances bone formation in mice. Bone 60, 162–171 (2014).
Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–4031 (1991).
Goldring, S.R. Inflammatory mediators as essential elements in bone remodeling. Calcif. Tissue Int. 73, 97–100 (2003).
Polzer, K. et al. Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 69, 284–290 (2010).
Scott, D.L. et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39, 122–132 (2000).
Goldring, S.R. Pathogenesis of bone erosions in rheumatoid arthritis. Curr. Opin. Rheumatol. 14, 406–410 (2002).
Tsuboi, H. et al. Tartrate resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage. Ann. Rheum. Dis. 62, 196–203 (2003).
Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419–1427 (2002).
Schett, G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 9, 203 (2007).
Suzuki, Y., Nishikaku, F., Nakatuka, M. & Koga, Y. Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 25, 1154–1160 (1998).
Walsh, N.C., Crotti, T.N., Goldring, S.R. & Gravallese, E.M. Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 208, 228–251 (2005).
Li, P. et al. RANK signalling is not required for TNF-α-mediated increase in CD11hi osteoclast precursors but is essential for mature osteoclast formation in TNF-α-mediated inflammatory arthritis. J. Bone Miner. Res. 19, 207–213 (2004).
Lam, J. et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481–1488 (2000).
Ritchlin, C.T., Haas-Smith, S.A., Li, P., Hicks, D.G. & Schwarz, E.M. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111, 821–831 (2003).
Bertolini, D.R., Nedwin, G.E., Bringman, T.S., Smith, D.D. & Mundy, G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516–518 (1986).
Bradley, L., Yaworsky, P.J. & Walsh, F.S. Myostatin as a therapeutic target for musculoskeletal disease. Cell. Mol. Life Sci. 65, 2119–2124 (2008).
Fuller, K., Bayley, K.E. & Chambers, T.J. Activin A is an essential cofactor for osteoclast induction. Biochem. Biophys. Res. Commun. 268, 2–7 (2000).
Sugatani, T., Alvarez, U.M. & Hruska, K.A. Activin A stimulates IκB-α/NFκB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J. Cell. Biochem. 90, 59–67 (2003).
Tani-Ishii, N., Tsunoda, A., Teranaka, T. & Umemoto, T. Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha. J. Dent. Res. 78, 1617–1623 (1999).
Korb-Pap, A. et al. Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann. Rheum. Dis. 71, 1004–1011 (2012).
Lee, Z.H. & Kim, H.H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211–214 (2003).
Lee, S.E. et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30, 71–77 (2002).
Li, X. et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105–3113 (2002).
Omata, Y. et al. Genome-wide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. J. Bone Miner. Res. 30, 869–877 (2015).
Li, Z.B., Kollias, H.D. & Wagner, K.R. Myostatin directly regulates skeletal muscle fibrosis. J. Biol. Chem. 283, 19371–19378 (2008).
Machida, H., Ogawa, K., Funaba, M., Mizutani, T. & Tsujimoto, M. mRNA expression of type I and type II receptors for activin, transforming growth factor-beta, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.fl. Eur. J. Endocrinol. 143, 705–710 (2000).
Kaneto, H. et al. Increased expression of TGF-β1 but not its receptor contributes to human obstructive nephropathy. Kidney Int. 56, 2137–2146 (1999).
Inman, G.J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65–74 (2002).
Holzbaur, E.L. et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol. Dis. 23, 697–707 (2006).
Monach, P.A., Mathis, D. & Benoist, C. The K/BxN arthritis model. Curr. Protoc. Immunol. 81, 15.22.1–15.22.12 (2008).
Martinez, G.J. et al. Smad2 positively regulates the generation of Th17 cells. J. Biol. Chem. 285, 29039–29043 (2010).
We thank S.-J. Lee (Johns Hopkins University School of Medicine) for providing us with the Mstn−/− mice, and G. Kollias (Alexander Fleming Biomedical Sciences Research Center) for the hTNF transgenic mice. We also thank Pfizer, Inc. for providing us with the myostatin-specific antibody. We thank X. Lin (Department of Surgery, Baylor College of Medicine) for providing us with the SMAD2 constructs. We thank V. Eckervogt and B. Truckenbrod for excellent technical support. This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; DA 1143/4-1 and DA 1143/4-2 to B.D. and T.P. as part of the Priority Programme SPP 1468, IMMUNOBONE) and by the Collaborative Research Center SFB 1009 granted to T.P.
The authors declare no competing financial interests.
About this article
Cite this article
Dankbar, B., Fennen, M., Brunert, D. et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat Med 21, 1085–1090 (2015) doi:10.1038/nm.3917
Contribution of Inflammation and Bone Destruction to Pain in Arthritis: A Study in Murine Glucose‐6‐Phosphate Isomerase–Induced Arthritis
Arthritis & Rheumatology (2019)
Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis
Genome Research (2019)
Physical Activity and Bone Health: What Is the Role of Immune System? A Narrative Review of the Third Way
Frontiers in Endocrinology (2019)